skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Management of chronic hepatitis C treatment failures: role of consensus interferon

Review

(2771) Views  (700) Full article downloads

Authors: Stevan A Gonzalez, Emmet B Keeffe

Published Date March 2009 Volume 2009:3 Pages 141 - 150
DOI: http://dx.doi.org/10.2147/BTT.S3970

Stevan A Gonzalez1, Emmet B Keeffe2

1Division of Hepatology, Baylor Regional Transplant Institute, Baylor All Saints Medical Center, Fort Worth and Baylor University Medical Center, Dallas, TX, USA; 2Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University Medical Center, Stanford, CA, USA

Abstract: A significant proportion of patients with chronic hepatitis C virus (HCV) infection who undergo antiviral therapy have persistent or recurrent viremia and fail to achieve a sustained virologic response (SVR). Factors associated with treatment failure include HCV genotype 1 infection, high serum HCV RNA levels, and advanced fibrosis. Consensus interferon (CIFN) is a synthetic type I interferon derived from a consensus sequence of the most common amino acids found in naturally occurring alpha interferon subtypes. Several prospective clinical studies have demonstrated that CIFN may be a treatment option in patients who have failed prior interferonbased therapy, including those who have failed combination therapy with standard interferon or peginterferon plus ribavirin. Daily CIFN in combination with ribavirin may be an effective regimen in this setting; however, optimal dose and treatment duration of CIFN therapy have not been well established. Patients who achieve viral suppression during prior interferon-based therapy and those who do not have advanced fibrosis have a greater likelihood of achieving a SVR with CIFN retreatment. Individualized therapy targeting specific patient groups will be an important consideration in the successful management of prior treatment failures. Additional prospective studies are required in order to identify optimal treatment strategies for the use of CIFN in these patients.

Keywords: consensus interferon, hepatitis C, interferon, nonresponder, relapser








Readers of this article also read:

Therapeutic vaccines for malignant brain tumors
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Finding a new drug and vaccine for emerging swine flu: What is the concept?
A combined phase I and II open label study on the effects of a seaweed extract nutrient complex on osteoarthritis
Safety and immunogenicity of Salmonella typhimurium expressing C-terminal truncated human IL-2 in a murine model
Hepatitis B virus and Homo sapiens proteomewide analysis: A profusion of viral peptide overlaps in neuron-specific human proteins
Prevention of rotavirus gastroenteritis in infants and children: rotavirus vaccine safety, efficacy, and potential impact of vaccines
Current status of vandetanib (ZD6474) in the treatment of non-small cell lung cancer
Gaucher disease: clinical profile and therapeutic developments
Effects of rituximab treatment on the serum concentrations of vitamin D and interleukins 2, 6, 7, and 10 in patients with rheumatoid arthritis
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University

  • Journal Indexing

    See where all the Dove Press journals are indexed